{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "NCT01270139",
            "NStudiesAvail": 430108,
            "NStudiesFound": 1,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 1,
            "FieldList": [
                  "EventGroupOtherNumAtRisk",
                  "EventGroupSeriousNumAffected",
                  "EventGroupSeriousNumAtRisk",
                  "EventGroupTitle",
                  "EventsDescription",
                  "EventsFrequencyThreshold",
                  "EventsTimeFrame",
                  "ExpAccTypeIndividual",
                  "ExpAccTypeIntermediate",
                  "ExpAccTypeTreatment",
                  "ExpandedAccessNCTId",
                  "ExpandedAccessStatusForNCTId",
                  "FDAAA801Violation",
                  "FlowAchievementComment",
                  "FlowAchievementGroupId",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "EventGroupOtherNumAtRisk": [
                              "42",
                              "34",
                              "40"
                        ],
                        "EventGroupSeriousNumAffected": [
                              "8",
                              "17",
                              "18"
                        ],
                        "EventGroupSeriousNumAtRisk": [
                              "42",
                              "34",
                              "40"
                        ],
                        "EventGroupTitle": [
                              "Nano Group",
                              "Ferro Group",
                              "Stenting Control"
                        ],
                        "EventsDescription": [
                              "Only parameters related to event free survival were assessed in patients who have completed the trial with the final follow-up. Some patients were excluded (64/180, a 35.6% of the intention-to-treat population) during the trial due to non-compliance, broken randomization codes or violations of the protocol."
                        ],
                        "EventsFrequencyThreshold": [
                              "0"
                        ],
                        "EventsTimeFrame": [
                              "12 months"
                        ],
                        "ExpAccTypeIndividual": [],
                        "ExpAccTypeIntermediate": [],
                        "ExpAccTypeTreatment": [],
                        "ExpandedAccessNCTId": [],
                        "ExpandedAccessStatusForNCTId": [],
                        "FDAAA801Violation": [],
                        "FlowAchievementComment": [
                              "Intention-to-treat population",
                              "Intention-to-treat population",
                              "Intention-to-treat population",
                              "Pre-treatment evaluable population",
                              "Pre-treatment evaluable population",
                              "Pre-treatment evaluable population"
                        ],
                        "FlowAchievementGroupId": [
                              "FG000",
                              "FG001",
                              "FG002",
                              "FG000",
                              "FG001",
                              "FG002",
                              "FG000",
                              "FG001",
                              "FG002"
                        ],
                        "NCTId": [
                              "NCT01270139"
                        ]
                  }
            ]
      }
}